Company Overview and News
(Reuters) - A U.S. threat that it may introduce tariffs on foreign auto imports drew strong criticism on Thursday from the country’s main business lobbying group, which warned of a “staggering” blow to the industry and the prospect of a global trade war.
MEXICO CITY/WASHINGTON (Reuters) - Mexican President Enrique Pena Nieto on Thursday expressed optimism about NAFTA talks that have been thrown into disarray by a U.S. probe exploring auto tariffs, while a source said Mexico had made a new offer to seek a deal.
Adding fuel to the ongoing trade tensions, the Trump administration has initiated a national security investigation into auto imports that may result in fresh tariffs. And U.S. President Donald Trump’s urging that any deal would need “a different structure” has stirred global trade worries all over again.
A Trump administration investigation of car and truck imports raised the threat on Thursday of renewed conflict over trade policy for an industry that thrives on stability and sent stocks in Asian and European automakers down.
WASHINGTON – The Trump administration has launched a national security investigation into car and truck imports that could lead to new U.S. tariffs similar to those imposed on imported steel and aluminum in March.
The Trump administration is considering a proposal to impose new tariffs on imported vehicles invoking a national security law that was used to impose tariffs on aluminum and steel, an administration official and three industry officials who had been briefed on the matter said.
Toyota Motor Corp on Thursday said it plans to build a plant to manufacture hydrogen fuel cell stacks, a key component of fuel cell vehicles, as it seeks to mass manufacture hydrogen-powered cars to expand their usage as a zero emissions alternative to gasoline vehicles.
MEXICO CITY/WASHINGTON: Mexico will not buckle to pressure to conclude the long-stalled renegotiation of NAFTA, President Enrique Pena Nieto's spokesman said on Thursday (May 25), but a source said the country made a new offer after the United States launched a probe exploring auto tariffs.
Beijing: A day after China delivered on its promise to cut auto import tariffs, Tesla Inc. lowered prices in the country by about 6%, passing on some of the savings to consumers as competition heats up in the world’s largest electric-car market.
SHANGHAI/BEIJING/TOKYO – China will steeply cut import tariffs for automobiles and car parts, opening up greater access to the world’s largest auto market amid an easing of trade tensions with the United States.
Tesla Inc has slashed up to US$14,000 off its Model X in China after Beijing announced major tariff cuts for imported automobiles, a potential sales boost for the U.S. firm as the world's largest auto market pivots towards electric cars.
BEIJING (Reuters) - Tesla Inc (TSLA.O) has slashed up to $14,000 off its Model X in China after Beijing announced major tariff cuts for imported automobiles, a potential sales boost for the U.S. firm as the world’s largest auto market pivots towards electric cars.
Emissions from gas-guzzling combustion engines have prompted the auto industry to focus more on electric vehicles. Further, government regulations have strengthened the preference for electric vehicles (EVs) over other combustion-engine based vehicles.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SHANGHAI/BEIJING (Reuters) - China will steeply cut import tariffs for automobiles and car parts, opening up greater access to the world’s largest auto market amid an easing of trade tensions with the United States.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...